Neotigason (Acitretin)

Acitretin binds to nuclear retinoic acid receptors and retinoid X receptors, modifying gene expression that controls keratinocyte differentiation and proliferation. This normalizes epidermal growth, reduces hyperkeratinization, and exerts anti‑inflammatory effects that improve psoriatic skin lesions.

The dosage of Neotigason is individualized. A qualified prescriber determines the starting dose, titration schedule, and maintenance dose based on the severity of disease, patient weight, liver function, and lipid profile, following local prescribing guidelines.

Acitretin is classified as pregnancy category X and is contraindicated in pregnancy because of its strong teratogenic potential. Women of childbearing potential must use effective contraception during treatment and for at least three years after stopping. Use during breastfeeding is not recommended.

To order Neotigason, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required cold‑chain handling) and import documentation.

Compared with systemic agents such as methotrexate, acitretin offers a non‑immunosuppressive oral option that primarily targets keratinocyte proliferation. Biologic therapies provide higher efficacy for some patients but require injection and are more costly. Choice of therapy depends on disease severity, comorbidities, and patient preference.

Neotigason capsules should be stored at ambient temperature, preferably below 25 °C, in the original blister pack. Protect them from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Neotigason is taken orally as a capsule with a full glass of water. It is usually recommended to swallow the capsule with food to improve tolerability, although specific instructions should follow the prescribing physician’s advice.

Serious risks include hepatotoxicity (elevated liver enzymes or liver injury), severe hyperlipidemia, pseudotumor cerebri (increased intracranial pressure), and teratogenic effects. Patients should report persistent abdominal pain, visual disturbances, severe skin reactions, or any signs of liver dysfunction promptly.

Neotigason should not be used by pregnant women, women planning pregnancy, or those who cannot ensure effective contraception for three years after discontinuation. It is also contraindicated in children, patients with uncontrolled hyperlipidemia, severe liver disease, or known hypersensitivity to acitretin or other retinoids.